Minoryx Therapeutics

Focus: Minoryx Therapeutics is a Barcelona-based biotechnology company focused on developing small molecule therapeutics for rare neurological diseases, with a pipeline targeting adrenoleukodystrophy and Friedreich ataxia.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Minoryx Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Minoryx Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Disease Progression in Women With X-linked Adrenoleukodystrophy

X-linked Adrenoleukodystrophy

N/A

Clinical Trials (1)

NCT06178120Disease Progression in Women With X-linked Adrenoleukodystrophy

N/A

Help build intelligence for Minoryx Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused rare disease niche with high unmet medical need and potential for breakthrough approvals in orphan indications
Pipeline includes 5 active programs with 2 in Phase 3 development, offering mid-to-late stage clinical exposure
Based in Barcelona with access to European regulatory pathways and rare disease expertise

Watch Out For

No active job openings currently listed, suggesting limited near-term hiring momentum
Pre-revenue status with undisclosed funding and financial position creates stability uncertainty

Generated by Claude from Minoryx Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MIN-102

Friedreich Ataxia

Phase 2

Clinical Trials (1)

NCT03917225A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

Phase 2

MIN-102

Cerebral Adrenoleukodystrophy

Phase 2

Clinical Trials (1)

NCT04528706A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

Phase 2

MIN-102

Adrenoleukodystrophy

Phase 2/3

Clinical Trials (1)

NCT03231878A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

Phase 2/3

Leriglitazone

Cerebral Adrenoleukodystrophy (cALD)

Phase 3

Clinical Trials (1)

NCT05819866A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline